Beijing Hotgen Biotech Co.,Ltd(688068.SH): Innovative drug AA001 monoclonal antibody Ib phase clinical study completed the first dose of Alzheimer's disease subjects.

Beijing Hotgen Biotech Co., Ltd (688068.SH) announced that recently, the company has received a report from its equity company, Shenzhen Genesee Biotech Limited (referred to as "Genesee Biotech"), through its wholly-owned subsidiary Beijing Genesee Hong Sheng Biotech Limited (referred to as "Genesee Hong Sheng"), regarding the completion of the first dose administration of the innovative drug AA001 monoclonal antibody in a Phase Ib clinical study on Alzheimer's disease patients. It is reported that the "Evaluation of the safety, tolerability, and preliminary efficacy of AA001 monoclonal antibody in Chinese patients with Alzheimer's disease-related mild cognitive impairment and mild Alzheimer's disease: a randomized, double-blind, placebo-controlled, dose-escalation Phase Ib clinical trial" conducted by Genesee Hong Sheng is led by Professor Tang Yi and Professor Wei Cuibai from Capital Medical University Xuanwu Hospital, with a total of seven clinical centers nationwide participating. The study has been approved by the Ethics Committee of Capital Medical University Xuanwu Hospital and has successfully completed the first subject's enrollment and drug administration recently.